European Egyptian Pharmaceutical Industries Report issue

For profit Phase 1 Phase 3
Founded: Alexandria Egypt (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2011
NCT01531517
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

European Egyptian Pharmaceutical Industries

Active Ingredients

Drugs in Phase 3 Trials (1)

panthenol (2 trials)

Drugs in Phase 1 Trials (2)

daclatasvir (daklinza) (1 trial)

favipiravir (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Foot (Phase 3)

Foot Ulcer (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3